Drugs / Pneumococcal 13-valent Conjugate Vaccine (PCV13)
Pneumococcal 13-valent Conjugate Vaccine (PCV13)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03848065 Comparator | Apr 2019 → Jun 2020 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumococcal 13-valent Conjugate Vaccine (PCV13) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03848065 ↗ |
| Modality | Vaccine | “13-valent PCV (PCV13)-SC” PMID 36882898 ↗ Mar 2023 |
| Route | Subcutaneous | “single 0.5 mL subcutaneous (SC) injection of pneumococcal 13-valent conjugate vaccine (PCV13)” NCT03848065 ↗ |